Daniel Markowitz
Stock Analyst at Evercore ISI Group
(2.85)
# 4,060
Out of 5,182 analysts
36
Total ratings
44.44%
Success rate
1.05%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGEN Repligen | Maintains: Outperform | $170 → $140 | $117.60 | +19.05% | 6 | Apr 6, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $170 → $118 | $110.93 | +6.37% | 3 | Apr 6, 2026 | |
| TECH Bio-Techne | Maintains: In-Line | $68 → $54 | $54.19 | -0.34% | 5 | Apr 6, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $85 → $62 | $56.31 | +10.10% | 3 | Apr 6, 2026 | |
| GH Guardant Health | Maintains: In-Line | $110 → $90 | $88.91 | +1.23% | 5 | Apr 6, 2026 | |
| MMED MiniMed Group | Initiates: Outperform | $20 | $13.20 | +51.52% | 1 | Mar 31, 2026 | |
| NTRA Natera | Maintains: Outperform | $250 → $260 | $203.75 | +27.61% | 3 | Feb 27, 2026 | |
| PODD Insulet | Maintains: Outperform | $370 → $340 | $189.56 | +79.36% | 2 | Feb 19, 2026 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $390 → $320 | $306.16 | +4.52% | 4 | Feb 3, 2026 | |
| RMBS Rambus | Maintains: Outperform | $126 → $119 | $158.40 | -24.87% | 3 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: In-Line | $68 | $61.57 | +10.44% | 1 | Nov 25, 2025 |
Repligen
Apr 6, 2026
Maintains: Outperform
Price Target: $170 → $140
Current: $117.60
Upside: +19.05%
TransMedics Group
Apr 6, 2026
Maintains: Outperform
Price Target: $170 → $118
Current: $110.93
Upside: +6.37%
Bio-Techne
Apr 6, 2026
Maintains: In-Line
Price Target: $68 → $54
Current: $54.19
Upside: -0.34%
Inspire Medical Systems
Apr 6, 2026
Maintains: Outperform
Price Target: $85 → $62
Current: $56.31
Upside: +10.10%
Guardant Health
Apr 6, 2026
Maintains: In-Line
Price Target: $110 → $90
Current: $88.91
Upside: +1.23%
MiniMed Group
Mar 31, 2026
Initiates: Outperform
Price Target: $20
Current: $13.20
Upside: +51.52%
Natera
Feb 27, 2026
Maintains: Outperform
Price Target: $250 → $260
Current: $203.75
Upside: +27.61%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $370 → $340
Current: $189.56
Upside: +79.36%
West Pharmaceutical Services
Feb 3, 2026
Maintains: Outperform
Price Target: $390 → $320
Current: $306.16
Upside: +4.52%
Rambus
Feb 3, 2026
Maintains: Outperform
Price Target: $126 → $119
Current: $158.40
Upside: -24.87%
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $61.57
Upside: +10.44%